BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38664770)

  • 41. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.
    Sotelo MJ; Sastre J; Maestro ML; Veganzones S; Viéitez JM; Alonso V; Grávalos C; Escudero P; Vera R; Aranda E; García-Alfonso P; Gallego-Plazas J; Lopez C; Pericay C; Arrivi A; Vicente P; Ballesteros P; Elez E; López-Ladrón A; Díaz-Rubio E
    Ann Oncol; 2015 Mar; 26(3):535-41. PubMed ID: 25515656
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma.
    Lee BS; Lee SH; Son JH; Jang DK; Chung KH; Paik WH; Ryu JK; Kim YT
    J Gastroenterol Hepatol; 2016 Feb; 31(2):493-500. PubMed ID: 26220764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
    Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic Role of a Multimarker Analysis of Circulating Tumor Cells in Advanced Gastric and Gastroesophageal Adenocarcinomas.
    Kubisch I; de Albuquerque A; Schuppan D; Kaul S; Schaich M; Stölzel U
    Oncology; 2015; 89(5):294-303. PubMed ID: 26315108
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
    Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carcinoembryonic antigen, α-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: A retrospective cohort study.
    Qiang Z; Zhang W; Jin S; Dai K; He Y; Tao L; Yu H
    Ann Hepatol; 2021; 20():100242. PubMed ID: 32841741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer.
    Yamashita S; Passot G; Aloia TA; Chun YS; Javle M; Lee JE; Vauthey JN; Conrad C
    Br J Surg; 2017 Feb; 104(3):267-277. PubMed ID: 28052308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
    Zhu C; Li H; Yang X; Wang S; Wang Y; Zhang N; Wang Y; Xue J; Zhang L; Ning C; Yang X; Xun Z; Chao J; Long J; Sang X; Zhu Z; Zhao H
    Cancer Immunol Immunother; 2023 Sep; 72(9):2949-2960. PubMed ID: 37247023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma.
    Liu CH; Huang Q; Jin ZY; Xie F; Zhu CL; Liu Z; Wang C
    J Cancer Res Ther; 2018 Jan; 14(1):220-225. PubMed ID: 29516989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
    Lindsay CR; Blackhall FH; Carmel A; Fernandez-Gutierrez F; Gazzaniga P; Groen HJM; Hiltermann TJN; Krebs MG; Loges S; López-López R; Muinelo-Romay L; Pantel K; Priest L; Riethdorf S; Rossi E; Terstappen L; Wikman H; Soria JC; Farace F; Renehan A; Dive C; Besse B; Michiels S
    Eur J Cancer; 2019 Aug; 117():60-68. PubMed ID: 31254940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes.
    Aoba T; Ebata T; Yokoyama Y; Igami T; Sugawara G; Takahashi Y; Nimura Y; Nagino M
    Ann Surg; 2013 Apr; 257(4):718-25. PubMed ID: 23407295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
    Chalfin HJ; Pramparo T; Mortazavi A; Niglio SA; Schonhoft JD; Jendrisak A; Chu YL; Richardson R; Krupa R; Anderson AKL; Wang Y; Dittamore R; Pal SK; Lara PN; Stein MN; Quinn DI; Steinberg SM; Cordes LM; Ley L; Mallek M; Sierra Ortiz O; Costello R; Cadena J; Diaz C; Gulley JL; Dahut WL; Streicher H; Wright JJ; Trepel JB; Bottaro DP; Apolo AB
    Clin Cancer Res; 2021 Mar; 27(5):1391-1398. PubMed ID: 33262136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
    Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative gamma-glutamyltransferase to lymphocyte ratio predicts long-term outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection.
    Wang JJ; Li H; Li JX; Xu L; Wu H; Zeng Y
    World J Gastroenterol; 2020 Apr; 26(13):1501-1512. PubMed ID: 32308350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
    Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
    Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China.
    Li J; Fu W; Zhang W; Li P
    Med Sci Monit; 2018 Jan; 24():324-331. PubMed ID: 29337932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.